News

Arch Biopartners and  Catalent Inhalation, a division of Catalent Pharma Solutions, have entered agreements to start manufacturing AB569 for human trials in patients with chronic and antibiotic resistant bacterial lung infections. Representing a large part of the group affected, patients with cystic fibrosis  (CF) stand to benefit most. AB569, invented by Daniel Hassett,…

The Japanese Patent Office has granted AmpliPhi Biosciences a patent for the “Beneficial effects of bacteriophage treatments” targeting Pseudomonas aeruginosa infections. A similar patent has already been granted in the United States and a request for one has been filed in Canada. In Australia and in the European…

New four-dimensional computed tomography (4DCT) for lung scans, developed by Professor Andreas Fouras at Monash University, offers the potential to revolutionize treatment for the millions of patients worldwide with lung diseases like cystic fibrosis. The 4DxV X-ray imaging technology, developed and commercialized by Professor Fouras’ technology company 4Dx, provides a state-of-the-art, noninvasive…

A team of scientists from Ulster University, in Northern Ireland, United Kingdom, have joined a nearly $980,000  global research study seeking alternative treatment options for patients with cystic fibrosis-related diabetes (CFRD). The new three-year Strategic Research Centre (SRC) study is the first of its kind funded by the Cystic Fibrosis Trust…

Cystic fibrosis (CF) is a condition known to be linked to lung problems, but bone health can also be impacted in people with the disease. A new paper from researchers in the United Kingdom focuses on this problem. The report, “Bone health and disease in cystic fibrosis,“…

A recent study from Belgium showed that a common bacterium found in the lungs of people with cystic fibrosis (CF) might be converted to a less dangerous form, and could possibly aid in the development of treatments for the disease. The research report, “Effect of Shear Stress on Pseudomonas aeruginosa Isolated…

The San Diego Chapter of the Cystic Fibrosis Foundation will host its inaugural Surf for CF day on the beach at La Jolla Shores on Sept. 24, raising awareness and funds for cystic fibrosis (CF). The two-part event will feature free surf lessons for 25 cystic fibrosis patients in the morning,…

Spine deformities that are sometimes seen in cystic fibrosis (CF) may be adequately corrected with minimal risk through multidisciplinary care during surgery and meticulous surgical techniques, as reported by a case study reviewed in the article “Scoliosis Surgery in Cystic Fibrosis: Surgical Considerations and the Multidisciplinary Approach of a Rare Case.”

Canadian patients with cystic fibrosis (CF) will have to wait for access to Orkambi (lumacaftor/ivacaftor), whose submission will be reconsidered at a future meeting by the Canadian Drug Expert Committee (CDEC) of the Canadian Agency for Drugs and Technologies in Health (CADTH). CADTH is the nonprofit Canadian organization that makes recommendations for a…

The Cystic Fibrosis Foundation Therapeutics (CFFT) recently awarded Laurent Pharmaceuticals a Therapeutics Development Award, valued to up to $3 million, to support a Phase 2 clinical trial evaluating the company’s drug candidate, LAU-7b, as a potential treatment for cystic fibrosis (CF). “People with CF have an exaggerated and persistent inflammatory response to…